Pulmonary exacerbation rates after three years of Elexacaftor/Tezacaftor/Ivacaftor therapy in adults with cystic fibrosis and severe lung disease - Adult Cystic Fibrosis Conference, 2023

Treatment and management (2)

Chair(s): James D. Chalmers, Sarah Collins

Session type: Oral presentation

Pulmonary exacerbation rates after three years of Elexacaftor/Tezacaftor/Ivacaftor therapy in adults with cystic fibrosis and severe lung disease

Daniela Savi

EVENTS HOME

Previous presentation

Next presentation

Session content

The Neuropsychiatric Implications of CFTR Modulator Therapy in Cystic Fibrosis Patients: A Systematic Review and Analysis of Regulatory Data

Jacob O'connor

e-poster

A 5-year monocentric retrospective analysis of the use of Ceftazidim/Avibactam and Ceftolozane/Tazobactam in adult cystic fibrosis patients

Till Othmer

e-poster

Bacteriophage therapy in cystic fibrosis patients - a comprehensive analysis of the outcomes and statistics at the Eliava Phage Therapy Center

Mariam Dadiani

e-poster

HETEROGENEITY IN TREATMENT RESPONSE TO ELEXACAFTOR-TEZACAFTOR-IVACAFTOR IN PEOPLE WITH CYSTIC FIBROSIS

Federica Bellino

Outcomes of short-term modulatory therapy in adult cystic fibrosis

Aytekin Idikut

e-poster

CFTR Modulator Therapy Rescues CFTR and Lowers P2X7R-induced Inflammasome Activation of Airway Epithelial Cells

Debananda Gogoi

e-poster

Pulmonary exacerbation rates after three years of Elexacaftor/Tezacaftor/Ivacaftor therapy in adults with cystic fibrosis and severe lung disease

Daniela Savi

e-poster

Patients not eligible for CFTR-modulators (CFTRm) in Europe: characteristics and distribution

Irene Tomarelli

e-poster

Long-term effectiveness and safety of Elexacaftor/Tezacaftor/Ivacaftor in daily practice of a Portuguese Cystic Fibrosis Reference Centre

Elsa Guerreiro Da Cunha Fragoso

e-poster

Effect of elexacaftor/tezacaftor/ivacaftor on body plethysmography measurements in patients with cystic fibrosis and advanced lung disease.

Chiara Premuda

e-poster

#{title}